Crucell forges vaccine pact with Sanofi

The Dutch biotech Crucell will pocket a €10 million up front payment and up to €66.5 million in milestone payments after forging a collaboration and marketing deal with Sanofi Pasteur for its rabies monoclonal antibodies. Sanofi Pasteur has a well developed market for vaccines to combat pre- and post-exposure rabies.

"Adding a next generation rabies treatment to our well-established rabies product range will further position the company as a leading force to help prevent this fatal disease," said Wayne Pisano, the CEO of Sanofi Pasteur. The deal was announced this morning.

- see this release
- read the report from Thomson Financial

Suggested Articles

Sanofi didn't hesitate to enter Zika vaccine R&D, and despite the associated scandal, the company is again jumping into emerging disease vaccine R…

NIH and Moderna will need a coronavirus vaccine manufacturer, and and no major pharmaceutical company has stepped up.

GlaxoSmithKline’s vaccines unit has been a bright spot for the company, but its performance doesn’t make it immune to staff cuts.